Phase 2 Discovery, Inc.

Cincinnati, OH 45219

SBIR Award Summary

Total Number of Awards 21
Total Value of Awards $4.43MM
First Award Date 09/27/01
Most Recent Award Date 12/01/04

Key Personnel

Last Name Name Awards Contact
Mulchahey James Jeffrey Mulchahey 4
Choi Anthony H Choi 1
Zemlan Frank P Zemlan 12
Gabbita Somasundar Prasad Gabbita 2
Norman Andrew B Norman 2

21 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 12/01/04 - 11/30/05

DESCRIPTION (provided by applicant): Despite an understanding of the pharmacological basis of cocaine abuse there is no effective pharmacotherapy, suggesting that pharmacotherapy may be impractical. An alternative approach is to: develop an immunotherapy that directly targets cocaine. We have generated a fully human anti-cocaine monoclonal antib...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 11/30/04

DESCRIPTION (provided by applicant): Despite an understanding of the pharmacological basis of cocaine abuse there is no effective pharmacotherapy, suggesting that pharmacotherapy may be impractical. An alternative approach is to: develop an immunotherapy that directly targets cocaine. We have generated a fully human anti-cocaine monoclonal antib...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 05/01/04 - 11/30/06

DESCRIPTION (provided by applicant): Rotavirus causes severe diarrhea in infants resulting in approximately 600,000 deaths worldwide and costing the United States 1.5 billion dollars annually. The only FDA-approved rotavirus vaccine was withdrawn in 1999 because of its association with intussusception. The subunit rotavirus vaccines that we ar...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 03/31/06

DESCRIPTION (provided by applicant): The National Institute of Drug Abuse has indicated, "NIDA's top research priority is to find a medication to block or greatly reduce the effects of cocaine to be used as part of a comprehensive treatment program." The purpose of the present FAST TRACK Phase 1 application is to continue development of our prop...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/04 - 02/28/06

DESCRIPTION (provided by applicant): The objective of this Phase II application is to develop a sensitive quantitative biomarker of drug-induced neuronal degeneration, particularly associated with drugs of abuse. We have shown that during neuronal degeneration the neuronally localized protein MAP-tau is proteolytically cleaved (C-tau) in patient...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/04 - 12/31/05

DESCRIPTION (PROVIDED BY APPLICANT): Phase 2 Discovery is developing a synthetic melatonin analog (PD6735) for the treatment of sleep disorders. PD6735 is being developed as a safe and effective treatment for sleep disorders that lacks the side effects of current first-line sleep medications. Initial clinical studies indicate that PD6735 is sa...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 08/31/05

DESCRIPTION (provided by applicant): The pharmaceutical industry has spent $200 million on drug trials for treating head trauma, all have failed, Identified problems include inappropriate selection of drug candidates, and failure to use prognostic indicators and surrogate biomarkers in clinical trials. Proposed Phase I...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/03 - 12/31/04

DESCRIPTION (provided by applicant): The objective of the present Phase 1 feasibility study is to develop a quantitative serum-based biomarker for detecting neuronal damage in mild traumatic brain injury (TBI). Postconcussion Syndrome (PCS) is believed to be the cause for much if not all of the disability suffered by mild TBI patients. Although ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/03 - 03/31/04

DESCRIPTION (provided by applicant): The objective of this Phase I feasibility study is to develop a reliable biomarker of neuronal damage in a validated mouse model of amyotrophic lateral sclerosis (ALS). Currently, there is no widely accepted biomarker to quantify ALS-induced motor neuron injury. Previously, we have shown that neuronal degener...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/03/03 - 12/31/03

DESCRIPTION (PROVIDED BY APPLICANT): Phase 2 Discovery is developing a synthetic melatonin analog (PD6735) for the treatment of sleep disorders. PD6735 is being developed as a safe and effective treatment for sleep disorders that lacks the side effects of current first-line sleep medications. Initial clinical studies indicate that PD6735 is sa...

Load More